Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY):a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial (vol 397, pg 475, 2021)

Gordon K. B.; Foley P.; Krueger J. G.

首页> 外文期刊>The Lancet >Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY):a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial (vol 397, pg 475, 2021)

【24h】

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY):a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial (vol 397, pg 475, 2021)

机译：Bimekizumab疗效和安全性中度至重度斑块牛皮癣（准备好）：多期，双盲，安慰剂控制，随机撤离第3阶段试验（第397 Vol 397，PG 475,2021）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Lancet》 |2021年第10280期|共1页
作者
Gordon K. B.; Foley P.; Krueger J. G.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献

1. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind,placebo-controlled multicenter trial [J] . YANG Hai-zhen, LIU Xiao-ming, TU Cai-xia, 中华医学杂志（英文版） . 2012,第011期
2. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial [J] . Gordon Kenneth B., Foley Peter, Krueger James G., The Lancet . 2021,第10273期

机译：Bimekizumab疗效和安全性中度至重度斑块的牛皮癣（准备就绪）：多期，双盲，安慰剂控制，随机戒断第3阶段试验
3. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial (vol 397, pg 487, 2021) [J] . Reich K., Papp K. A., Blauvelt A. The Lancet . 2021,第10275期

机译：Bimekizumab与Ustekinumab用于治疗中度至重度斑块的牛皮癣（生动）：52周，多方面，双盲，活跃的比较器和安慰剂控制第3阶段试验的功效和安全性（Vol 397，PG 487,2021）
4. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial (vol 397, pg 2169, 2021) [J] . Reich K., Teixeira H. D., de Bruin-Weller M. The Lancet . 2021,第10292期

机译：upadacitinib的安全性和有效性与中度至重度特性皮炎的青少年和成人局部皮质类固醇组合（广告）：随机，双盲，安慰剂控制，第3阶段试验（Vol 397，PG 2169， 2021）
5. A Phase IIIb Multicentre Randomised Parallel-Group Placebo-Controlled Double-Blind Study to Investigate the Efficacy and Safety of OROS Hydromorphone in Subjects with Moderate-to-Severe Chronic Pain Induced by Osteoarthritis of the Hip or the Knee [O] . Jozef Vojtaššák, Jozef Vojtaššák, Adam Jacobs, 2011

机译：IIIb期多中心随机平行组安慰剂对照双盲研究旨在研究OROS氢吗啡酮在中度至重度由髋或膝骨关节炎引起的中度至重度慢性疼痛患者中的疗效和安全性
6. Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal [O] . K Gordon, P Foley, JG Krueger, 2020

机译：Bimekizumab在中度至重度斑块牛皮癣患者中的功效和安全性：准备好的结果，56周第3期，随机戒断的随机分配，双盲，安慰剂对照研究

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY):a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial (vol 397, pg 475, 2021)

著录项

相似文献

相关主题

期刊订阅